As of July 31, 2025, cash, cash equivalents and marketable securities were $224.9 million. The Company expects that its existing cash, cash equivalents and marketable securities will fund operating expenses, debt obligations and capital expenditures into 2027. “Reaching target enrollment in LEGEND’s pivotal Cohort 1 and securing RMAT designation are important milestones that mark our continued momentum,” said Ron Cooper, CEO. “We look forward to providing a data update from the LEGEND pivotal cohort later this year. These advances bring us closer to our planned BLA filing in 2026 with the ultimate goal of delivering detalimogene to patients as a therapy designed for efficacy, safety, and ease-of-use.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- enGene Reaches Key Enrollment Milestone in LEGEND Trial for Bladder Cancer Therapy
- enGene achieves target enrollment in LEGEND trial of detalimogene voraplasmid
- enGene Holdings to Engage in September Investor Conferences
- enGene Holdings Grants Inducement Equity Awards to New Employees